8-K: Delcath Systems Announces Strong Preliminary 2024 Financial Results and Strategic Growth Plans

Delcath Systems reported robust preliminary financial results for 2024, highlighted by significant revenue growth and a strong cash position, while also outlining plans for future expansion.

Summary

• Delcath Systems has released preliminary unaudited financial results for the fourth quarter and full year of 2024.
• Total revenue for the fourth quarter is expected to be approximately $15.1 million, and full-year revenue is estimated at $37.2 million.
• HEPZATO KIT revenue is projected to be $13.7 million for the fourth quarter and $32.3 million for the full year.
• CHEMOSAT revenue is expected to be $1.4 million for the fourth quarter and $4.9 million for the full year.
• Gross margins are anticipated to be in the 80%-85% range.
• The company reported $53.2 million in cash, cash equivalents, and short-term investments with no debt as of December 31, 2024.
• As of December 31, 2024, there were 14 active sites utilizing the HEPZATO KIT and approximately 36.2 million shares of common stock issued and outstanding.
• The company plans to provide final financial results and a business update on March 6, 2025.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong preliminary financial results, a solid cash position, and clear growth plans. The company's product has a first-mover advantage and is showing strong market adoption. There are some risks mentioned, but the overall tone is optimistic.

Positives

• The company has shown significant revenue growth, particularly in HEPZATO KIT sales.
• The company has achieved high gross margins, indicating efficient operations.
• Delcath has a strong cash position with no debt, providing financial stability.
• The company is expanding its network of active treatment sites.
• The company has a first-mover advantage with the only FDA-approved whole-liver directed therapy.
• The company has a strong management team with expertise in commercializing high-value specialty products.
• The company has a clear path to profitability with a focus on high-value, specialty products.
• The company has a strong efficacy signal in multiple other tumor types beyond mUM.

Negatives

• The reported financial results are preliminary and unaudited, and actual results may vary.
• The company is still in the process of completing its financial close for 2024.
• The company is reliant on successful commercialization of HEPZATO KIT and management of its supply chain.
• The company is subject to risks related to FDA inspections and reimbursement for HEPZATO KIT.

Risks

• The preliminary financial results are subject to change due to audit adjustments and other factors.
• The company's success depends on the successful commercialization of the HEPZATO KIT.
• There are risks associated with managing the HEPZATO KIT supply chain and securing critical components.
• The company faces risks related to FDA inspections of its facilities and those of its suppliers.
• The company's ability to obtain reimbursement for HEPZATO KIT is a risk factor.
• The company's ability to enter into necessary purchase and sale agreements with users of the HEPZATO KIT is a risk factor.
• The company is subject to risks related to the timing and results of clinical trials.
• The company is subject to risks related to the impact of the COVID-19 pandemic or other pandemics on the completion of clinical trials.

Future Outlook

Delcath plans to continue expanding its commercial reach for HEPZATO KIT, explore additional indications for its technology, and advance its clinical programs, including the CHOPIN trial with results expected in the Fall of 2025. The company also anticipates receiving approximately $17 million from warrant exercises in Q2 2025.

Management Comments

• The company is focused on commercializing HEPZATO KIT and expanding its use to other cancer types.
• The management team has expertise in commercializing high-value, specialty products.
• The company is confident in its ability to achieve cash flow positivity.

Industry Context

Delcath operates in the interventional oncology space, focusing on liver-directed therapies. The company's HEPZATO KIT addresses a significant unmet need in treating liver-dominant cancers, particularly metastatic uveal melanoma. The company is competing with other liver-directed therapies such as TACE and SIRT, as well as systemic treatments like Kimmtrak. The company is also exploring the potential of combining its therapy with immune-oncology agents.

Comparison to Industry Standards

• Delcath's HEPZATO KIT is the first and only FDA-approved whole-liver directed therapy for metastatic uveal melanoma, giving it a competitive advantage over other liver-directed therapies like TACE and SIRT which are not approved for mUM.
• The company's reported gross margins of 80-85% are very strong compared to typical pharmaceutical and medical device companies.
• The company's cash position of $53.2 million with no debt is a strong indicator of financial health compared to many other biotech companies.
• The company's revenue growth is significant, with a 39% increase in HEPZATO KIT revenue from Q3 to preliminary Q4 2024, indicating strong market adoption.
• The company's clinical trial results for HEPZATO KIT show a median overall survival of 20.53 months, which is significantly higher than the median overall survival of 10.2 to 16.1 months reported in other studies for metastatic uveal melanoma using systemic and other liver-directed therapies.
• The company's planned expansion into other liver-dominant cancers such as colorectal cancer and breast cancer positions it for significant growth in a market with a high unmet need.

Stakeholder Impact

• Shareholders will likely view the strong financial results and growth plans positively.
• Employees may benefit from the company's growth and success.
• Patients with liver-dominant cancers will have access to a new treatment option.
• Healthcare providers will have a new tool for treating liver cancer.
• Suppliers and partners may benefit from increased demand for HEPZATO KIT.

Next Steps

• The company will provide final financial results and a business update on March 6, 2025.
• The company plans to continue expanding its commercial reach for HEPZATO KIT.
• The company will explore additional indications for its technology.
• The company will advance its clinical programs, including the CHOPIN trial.
• The company plans to initiate CRC and BCC trials.
• The company is targeting 30 active centers by the end of 2025.

Key Dates

Keywords

HEPZATO KIT, CHEMOSAT, liver cancer, metastatic uveal melanoma, interventional oncology, percutaneous hepatic perfusion, melphalan, financial results, revenue, gross margin